Statin Efficacy and Safety in T2DM by Cardiovascular Risk: A Target Trial Emulation

<h2 id="background">Background</h2><p>Statin benefit in type 2 diabetes mellitus (T2DM) patients with low predicted 10-year cardiovascular (CVD) risk remains undefined.</p><h2 id="objective">Objective</h2><p>Assess statin efficacy and safety for primary prevention in T2DM adults stratified by 10-year predicted CVD risk.</p><h2 id="methods">Methods</h2><ul><li>Matched cohort study (1:4 propensity score matching within risk strata) in U.K. primary care database.&nbsp;</li><li>Adults aged 25-84 years with T2DM diagnosis (2005-2016)</li><li>Excluded: prior coronary artery disease, myocardial infarction, stroke, heart failure, myopathy, liver disease, rheumatic heart disease, schizophrenia, or cancer.</li><li>Statin initiation versus noninitiation. Statin initiators matched 1:4 to noninitiators within 4 QRISK3 strata: low (&lt;10%), intermediate (10-19%), high (20-29%), very high (30%).</li><li>10-year absolute risk differences and risk ratios for all-cause mortality, major CVD, myopathy, and liver dysfunction were measured.</li></ul><h2 id="results">Results</h2><ul><li>Key findings showed the low-risk stratum outcomes and overall safety profile across all strata as given in Table.</li><li>Statin initiation reduced all-cause mortality and major CVD across all risk strata.</li><li>Myopathy risk increased in moderate-risk stratum only; no hepatic dysfunction risk detected.</li></ul><figure class="image"><img style="aspect-ratio:1078/247;" src="https://cdn.megawecare.com/GHBY/Internal-Images/ten-year-clinical-outcomes-by-baseline-cvd-risk-stratum.webp" alt="Ten Year Clinical Outcomes by Baseline CVD Risk Stratum" width="1078" height="247"></figure><h2 id="conclusion" data-section="conclusion">Conclusion</h2><p>Statin therapy provides cardiovascular and mortality benefit in T2DM regardless of baseline CVD risk.</p>

Cardiology Update 1   Issue 1   Jan 2026

<ul><li><a href="#background">Background</a></li><li><a href="#objective">Objective</a></li><li><a href="#methods">Methods</a></li><li><a href="#results">Results</a></li><li><a href="#conclusion">Conclusion</a></li></ul>

Statin Efficacy and Safety in T2DM by Cardiovascular Risk: A Target Trial Emulation

Reference